Evaluation of Clinical Laboratory Metrics in Adolescents with Moderate-to-Severe Atopic Dermatitis Receiving Tralokinumab for Up to 52 Weeks in the Phase 3 ECZTRA 6 Study - Takeaways - MDSpire

Evaluation of Clinical Laboratory Metrics in Adolescents with Moderate-to-Severe Atopic Dermatitis Receiving Tralokinumab for Up to 52 Weeks in the Phase 3 ECZTRA 6 Study

  • By

  • Amy S. Paller

  • Michael J. Cork

  • H. Chih-ho Hong

  • Weily Soong

  • Shannon K. R. Schneider

  • Hannah Lo

  • Frank Vinther

  • Patrick Thøgersen

  • Andreas Wollenberg

  • April 25, 2026

  • 0 min

Share

  • 1

    The ECZTRA 6 study evaluated tralokinumab's effects on clinical laboratory parameters in adolescents with moderate-to-severe atopic dermatitis.

  • 2

    Tralokinumab treatment resulted in transient eosinophil elevation and IgE level decrease, with no significant changes in other laboratory parameters.

  • 3

    Most laboratory parameters remained within reference ranges throughout the study, indicating a favorable safety profile for tralokinumab.

  • 4

    Tralokinumab treatment did not necessitate routine laboratory monitoring, supporting its use in managing moderate-to-severe atopic dermatitis.

  • 5

    The findings align with previous adult studies, reinforcing tralokinumab's consistent safety and efficacy in treating atopic dermatitis.

Original Source(s)

Evaluation of Clinical Laboratory Metrics in Adolescents with Moderate-to-Severe Atopic Dermatitis Receiving Tralokinumab for Up to 52 Weeks in the Phase 3 ECZTRA 6 Study

  • by Amy S. Paller, Michael J. Cork, H. Chih-ho Hong, Weily Soong, Shannon K. R. Schneider, Hannah Lo, Frank Vinther, Patrick Thøgersen, Andreas Wollenberg

  • April 25, 2026

Related Content

Americans trust Fauci more than RFK Jr.

Exploring Androgenetic Alopecia in Transgender and Gender-Diverse Populations: Insights on Characterization and Treatment Approaches

NPs Top US Jobs List Again

The nurse practitioner profession claims the No. 1 spot across three categories in the U.S. News & World Report 2026 Best Jobs rankings for the third consecutive year.